ArticleACS omega2026
Effects of Cp*-Ligands in Titanocene-Based Thiosemicarbazone Complexes.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Titanocene-based complexes are among the most prominent organometallic anticancer drugs. Since the discovery of titanocene dichloride, numerous derivatives have been tested as potential chemotherapeutic agents. We previously reported on titanocene-based drug carriers by using substitution-labile triflato ligands to generate cationic complexes with cytotoxic thiosemicarbazones (TSCN). Building on this, we posed the question of whether the larger cyclopentadiene derivative, pentamethylcyclopentadiene (Cp*), might further stabilize the organometallic drug carriers or provide other benefits such as increased lipophilicity. In this work, we describe the synthesis of titanocene-based complexes bearing Cp* and TSCN ligands and discuss how the Cp* ligands affect the water solubility and stability. Our findings are supported by DFT calculations, which enable a rational approach for the design of novel organometallic drug carriers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.